Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...
News Medical on MSN9d
Microbes in your gut could determine cancer treatment outcomesResearchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...
Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual ...
Hanx described the drug as a 'next-generation' immune-checkpoint inhibitor that represents a ‘breakthrough’ in cytotoxic T-lymphocyte–associated antigen 4 (CTLA ... any action on the basis ...
BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR ... Blocking monoclonal antibody CTLA-4 Phase III Ipilimumab Blocking monoclonal antibody CTLA-4 Phase II MDX-1106 Blocking monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback